Indication

In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)

Medicine details

Medicine name:
bevacizumab gamma (Lytenava)
SMC ID:
SMC2744
Pharmaceutical company
Outlook Therapeutics Ltd
BNF chapter
Eye
Submission type
Abbreviated
Publication due date:
12 May 2025